FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019156975> ?p ?o ?g. }

• W2019156975 endingPage "450" @default.
• W2019156975 startingPage "448" @default.
• W2019156975 abstract "Niacin has been known for decades to improve blood lipids. Its antiatherogenic potential was recently emphasized in the ARBITER 2 study [ [1] Taylor A.J. Sullenberger L.E. Lee H.J. Lee J.K. Grace K.A. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004; 110: 3512-3517 Crossref PubMed Scopus (866) Google Scholar ], in which it slowed down the increase in intima media thickness in patients with coronary heart disease when given in addition to simvastatin. Asymmetric dimethylarginine (ADMA) is a methylated amino acid which causes endothelial dysfunction by competitive inhibition of the NO synthase [ [2] Cooke J.P. Asymmetrical dimethylarginine. The Über Marker. Circulation. 2004; 109: 1813-1819 Crossref PubMed Scopus (363) Google Scholar ]. It is regarded as an independent risk factor for cardiovascular disease and has been shown to be of prognostic significance [ 3 Mallamaci F. Tripepi G. Cutrupi S. Malatino L.S. Zoccali C. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int. 2005; 67: 2330-2337 Crossref PubMed Scopus (118) Google Scholar , 4 Bae S.W. Stuhlinger M.C. Yoo H.S. et al. Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am J Cardiol. 2005; 95: 729-733 Abstract Full Text Full Text PDF PubMed Scopus (73) Google Scholar , 5 Valkonen V.P. Paiva H. Salonen J.T. et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 2001; 358: 2127-2128 Abstract Full Text Full Text PDF PubMed Scopus (518) Google Scholar ]. Niacin is usually applied in relatively large doses up to 2 g per day. The metabolization of such a niacin dose requires considerable amounts of methyl groups causing almost a doubling of the whole-body methyl-group demand [ [6] Mudd S.H. Poole J.R. Labile methyl balances for normal humans on various dietary regimens. Metabolism. 1975; 24: 721-735 Abstract Full Text PDF PubMed Scopus (390) Google Scholar ]. Therefore, we investigated if treatment with niacin would also affect other compounds requiring methyl groups such as ADMA or its inactive isomer, the symmetric dimethylarginine (SDMA)." @default.
• W2019156975 created "2016-06-24" @default.
• W2019156975 creator A5002413830 @default.
• W2019156975 creator A5005577019 @default.
• W2019156975 creator A5042254954 @default.
• W2019156975 creator A5061182191 @default.
• W2019156975 creator A5080157679 @default.
• W2019156975 date "2006-02-01" @default.
• W2019156975 modified "2023-09-25" @default.
• W2019156975 title "Treatment with niacin lowers ADMA" @default.
• W2019156975 cites W104265187 @default.
• W2019156975 cites W1557154008 @default.
• W2019156975 cites W1759912806 @default.
• W2019156975 cites W1963747418 @default.
• W2019156975 cites W1981268963 @default.
• W2019156975 cites W1983996159 @default.
• W2019156975 cites W1999405539 @default.
• W2019156975 cites W2005807653 @default.
• W2019156975 cites W2016889640 @default.
• W2019156975 cites W2069737615 @default.
• W2019156975 cites W2083441169 @default.
• W2019156975 cites W2088121802 @default.
• W2019156975 cites W2090170448 @default.
• W2019156975 cites W2104581763 @default.
• W2019156975 cites W2107959354 @default.
• W2019156975 cites W2132464590 @default.
• W2019156975 cites W2153110646 @default.
• W2019156975 cites W2166969544 @default.
• W2019156975 cites W2169002600 @default.
• W2019156975 cites W2169033201 @default.
• W2019156975 cites W2324490909 @default.
• W2019156975 doi "https://doi.org/10.1016/j.atherosclerosis.2005.11.018" @default.
• W2019156975 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16376893" @default.
• W2019156975 hasPublicationYear "2006" @default.
• W2019156975 type Work @default.
• W2019156975 sameAs 2019156975 @default.
• W2019156975 citedByCount "11" @default.
• W2019156975 countsByYear W20191569752012 @default.
• W2019156975 countsByYear W20191569752013 @default.
• W2019156975 countsByYear W20191569752015 @default.
• W2019156975 countsByYear W20191569752016 @default.
• W2019156975 countsByYear W20191569752018 @default.
• W2019156975 crossrefType "journal-article" @default.
• W2019156975 hasAuthorship W2019156975A5002413830 @default.
• W2019156975 hasAuthorship W2019156975A5005577019 @default.
• W2019156975 hasAuthorship W2019156975A5042254954 @default.
• W2019156975 hasAuthorship W2019156975A5061182191 @default.
• W2019156975 hasAuthorship W2019156975A5080157679 @default.
• W2019156975 hasConcept C126322002 @default.
• W2019156975 hasConcept C134018914 @default.
• W2019156975 hasConcept C164705383 @default.
• W2019156975 hasConcept C185592680 @default.
• W2019156975 hasConcept C2776329913 @default.
• W2019156975 hasConcept C2777468819 @default.
• W2019156975 hasConcept C2778213512 @default.
• W2019156975 hasConcept C2779473830 @default.
• W2019156975 hasConcept C2779877776 @default.
• W2019156975 hasConcept C2780092750 @default.
• W2019156975 hasConcept C2780972559 @default.
• W2019156975 hasConcept C500558357 @default.
• W2019156975 hasConcept C515207424 @default.
• W2019156975 hasConcept C55493867 @default.
• W2019156975 hasConcept C71924100 @default.
• W2019156975 hasConcept C83867959 @default.
• W2019156975 hasConceptScore W2019156975C126322002 @default.
• W2019156975 hasConceptScore W2019156975C134018914 @default.
• W2019156975 hasConceptScore W2019156975C164705383 @default.
• W2019156975 hasConceptScore W2019156975C185592680 @default.
• W2019156975 hasConceptScore W2019156975C2776329913 @default.
• W2019156975 hasConceptScore W2019156975C2777468819 @default.
• W2019156975 hasConceptScore W2019156975C2778213512 @default.
• W2019156975 hasConceptScore W2019156975C2779473830 @default.
• W2019156975 hasConceptScore W2019156975C2779877776 @default.
• W2019156975 hasConceptScore W2019156975C2780092750 @default.
• W2019156975 hasConceptScore W2019156975C2780972559 @default.
• W2019156975 hasConceptScore W2019156975C500558357 @default.
• W2019156975 hasConceptScore W2019156975C515207424 @default.
• W2019156975 hasConceptScore W2019156975C55493867 @default.
• W2019156975 hasConceptScore W2019156975C71924100 @default.
• W2019156975 hasConceptScore W2019156975C83867959 @default.
• W2019156975 hasIssue "2" @default.
• W2019156975 hasLocation W20191569751 @default.
• W2019156975 hasLocation W20191569752 @default.
• W2019156975 hasOpenAccess W2019156975 @default.
• W2019156975 hasPrimaryLocation W20191569751 @default.
• W2019156975 hasRelatedWork W133379348 @default.
• W2019156975 hasRelatedWork W1974808961 @default.
• W2019156975 hasRelatedWork W2019156975 @default.
• W2019156975 hasRelatedWork W2025645935 @default.
• W2019156975 hasRelatedWork W2049397185 @default.
• W2019156975 hasRelatedWork W2050245455 @default.
• W2019156975 hasRelatedWork W2308349949 @default.
• W2019156975 hasRelatedWork W2399063111 @default.
• W2019156975 hasRelatedWork W2417414779 @default.
• W2019156975 hasRelatedWork W2790353319 @default.
• W2019156975 hasVolume "184" @default.
• W2019156975 isParatext "false" @default.
• W2019156975 isRetracted "false" @default.

• next